CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
CCTG is pleased to announce the agenda for the Plenary Session at the #CCTG2026 Spring Meeting.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting
The Canadian Cancer Society (CCS) has launched its inaugural Data Transformation Grants to help transform cancer data and improve care. Apply for up to $125K for a 1-year project, from a funding envelope of ~$1M.
Reporting to the Team Leader, Ethics and Regulatory, the Ethics Research Associate will assist to conduct the ethics responsibilities of the Ethics and Regulatory (ER) office, within the Canadian Cancer Trials Group (CCTG).
Reporting and accountable to the Manager, Early Drug Development Program (EDDP), the Trial Team Leader will lead one of several teams in Trial Management Group (TMG). Teams are comprised primarily of study coordinators, research associates, and clinical trials assistants, who are involved in the coordination of clinical trials in cancer therapy, prevention and supportive care.
CRAFT - A Proposed Framework for Decentralized Clinical Trials Participation in Canada has been published in Current Oncology and is available online:
Just a reminder that Canadian Thanksgiving is fast approaching and our central office will be closed on Monday, October 11, 2021. We will reopen Tuesday, October 12, 2021 at 8;30 AM. Enjoy the holiday with your family and friends!
